Combine and conquer: challenges for targeted therapy combinations in early phase trials.
about
Maximising the potential of AKT inhibitors as anti-cancer treatmentsPhase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.Caffeic Acid Expands Anti-Tumor Effect of Metformin in Human Metastatic Cervical Carcinoma HTB-34 Cells: Implications of AMPK Activation and Impairment of Fatty Acids De Novo Biosynthesis.Dual inhibiting OCT4 and AKT potently suppresses the propagation of human cancer cells.Looking beyond the cancer cell for effective drug combinations.Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology EuroPredictive approaches for drug combination discovery in cancer.The evolving genomic landscape of urothelial carcinoma.Current status of research and treatment for non-small cell lung cancer in never-smoking females.High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Caffeic Acid and Metformin Inhibit Invasive Phenotype Induced by TGF-β1 in C-4I and HTB-35/SiHa Human Cervical Squamous Carcinoma Cells by Acting on Different Molecular Targets.Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines.Multifunctionalized biocatalytic P22 nanoreactor for combinatory treatment of ER+ breast cancer.The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer.Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies.Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1.GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets.Short- and long-term evolution in our arms race with cancer: Why the war on cancer is winnable.Next-Generation Modeling of Human CancersCommunity assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.
P2860
Q28072254-37C94A40-B22A-4C14-B7C7-31231CC03AB4Q33440037-17DAB91D-EB93-42FE-8597-FB7F307E6324Q37691088-46F73AB6-1756-4CF7-A740-0FD04E25AD49Q37739700-7B57CF3A-D048-47E5-BA17-C22B1AB983E2Q38728970-63F3D65D-8BA4-4DA8-9660-C649BEB72748Q38730798-69D3F646-DC84-4F00-B66E-365177839CAEQ39018410-4CC7972A-DE01-4318-A68E-E28EB06A5324Q39124491-BDFE0555-BC9B-42B0-8212-826504311802Q39298725-BD450AC7-E2B1-472D-950B-C9B63166BF04Q41523237-48B7879D-C220-4BD6-8092-5DCF245F2759Q41557167-6E201C98-9733-4434-B658-C831505ED3B0Q47325431-B0C90486-8201-419C-92F8-B1FA62B003FDQ48235688-7DEE7E5B-770B-4300-A612-0CB17986BDC6Q49657822-7FF536E2-8567-4FF7-B7FF-0F68A8F66913Q49795880-2C1C1A96-9250-456C-9855-28CBC3CE1DEEQ49835177-345AA8C8-8E85-4673-95C2-7E010895827CQ50097295-832BC0B1-5AB8-4D13-B2F4-CB29CF4CD86FQ52639446-7A3D69AE-336C-4100-AC48-DAE27BFCDE49Q53689773-A2721452-F7FF-44D4-8E95-1728F4C3F076Q55142863-2A46DCED-CFAF-487F-A1A4-6910A8C04FF9Q55465529-B0888F4F-0789-4AD2-BE4A-D71EB5609827Q58576103-47268C06-04AA-4FE7-AB62-127937E3FD2CQ64922122-3f88419c-4df2-bfa6-f156-68e712a546cb
P2860
Combine and conquer: challenges for targeted therapy combinations in early phase trials.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Combine and conquer: challenges for targeted therapy combinations in early phase trials.
@en
type
label
Combine and conquer: challenges for targeted therapy combinations in early phase trials.
@en
prefLabel
Combine and conquer: challenges for targeted therapy combinations in early phase trials.
@en
P2860
P1476
Combine and conquer: challenges for targeted therapy combinations in early phase trials
@en
P2093
Juanita S Lopez
P2860
P356
10.1038/NRCLINONC.2016.96
P407
P50
P577
2016-07-05T00:00:00Z